Ibio Inc (IBIO) 0.43 $IBIO
iBio Appoints Another IPF Expert, Dr. J. Terrill Huggins, to Clinical Advisory Board
Marketwire - Wed Jul 30, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed J. Terrill Huggins, M.D. to its clinical advisory board. The board of science and medical experts is assisting iBio in its clinical and product strategy.
iBio names Dr Richard M. Silver to clinical advisory board
M2 - Tue Jul 22, 8:30AM CDT
Plant biotechnology company iBio (NYSE MKT:IBIO) revealed on Monday the addition of Dr Richard M. Silver, MD to its clinical advisory board.
iBio Appoints Dr. Richard M. Silver to Clinical Advisory Board
Marketwire - Mon Jul 21, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed Richard M. Silver, M.D. to its recently formed clinical advisory board.
iBio elects Dr Timothy Blackwell as clinical advisory member
M2 - Thu Jul 17, 7:27AM CDT
Plant-based biotechnology company iBio (NYSE MKT:IBIO) disclosed on Wednesday the addition of Timothy Blackwell MD to its newly formed clinical advisory board.
iBio Appoints Dr. Timothy Blackwell to New Clinical Advisory Board
Marketwire - Wed Jul 16, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed Timothy Blackwell, M.D. to its newly formed clinical advisory board.
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lpdgx/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sangamo BioSciences, Inc. - Grifols, S.A. - rEVO Biologics - International Stem Cell Corporation - Kamada Ltd. - Dicerna Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - Applied Genetic Technologies Corporation - Intrexon Corporation - Polyphor Ltd. - iBio, Inc. - OrphageniX, Inc. - Carolus Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4lpdgx/alpha
Yellow Fever - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3x72t/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Yellow Fever - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Arbovax, Inc. - Crucell N.V. - Janssen Pharmaceuticals, Inc. - Medigen, Inc. - Panacea Biotec Limited - Themis Bioscience GmbH - iBio, Inc. For more information visit http://www.researchandmarkets.com/research/l3...llow_fever
iBio Expands Commercial Collaboration With Bio-Manguinhos and Fraunhofer
Marketwire - Wed Jun 18, 1:23AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, amended its multiproduct license and collaboration agreement with Brazil's Bio-Manguinhos/Fiocruz and the Fraunhofer USA Center for Molecular Biotechnology to enable expansion of joint work on an iBioLaunch(TM)-produced recombinant yellow fever vaccine and other products.
iBio awarded US patent for claims covering composition of matter and methods of use for endostatin-related peptides in treating IPF
M2 - Wed Jun 11, 5:37AM CDT
Biotechnology company iBio (NYSE MKT:IBIO) revealed on Tuesday the receipt of a patent from the US Patent and Trademark Office for its idiopathic pulmonary fibrosis (IPF) and systemic sclerosis product pipeline.
iBio Expands IP Protection of Biotherapeutic Product for Treatment of Fibrosis
Marketwire - Tue Jun 10, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the issue by the U.S. Patent and Trademark Office on May 6, 2014 of a new patent covering the company's idiopathic pulmonary fibrosis (IPF) and systemic sclerosis product pipeline.
Fabry Disease - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vktn6c/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Genzyme Corporation - Sanofi - Sangamo BioSciences, Inc. - Amicus Therapeutics, Inc. - Protalix BioTherapeutics, Inc. - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - greenovation Biotech GmbH - iBio, Inc. - Neuraltus Pharmaceuticals, Inc. - ISU ABXIS Co.,Ltd. - Biosidus S.A. For more information visit http://www.researchandmarkets.com/research/vk...ry_disease
iBio European Patent on iBioModulator Technology Emerges From Opposition Period
Marketwire - Thu Jun 05, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has surpassed the opposition period, expired on April 10, 2014, for a patent granted to the company by the European Patent Office. There is no indication that the patent has been opposed.
Human papillomavirus (HPV) Associated Cancer Therapeutics Pipeline Review 2014
M2 - Wed May 28, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jtm329/human) has announced the addition of the "Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Merck & Co., Inc. - 3SBio Inc. - Transgene SA - Prima BioMed Ltd. - Antigen Express, Inc. - Bionor Pharma ASA - PDS Biotechnology Corporation - Onconova Therapeutics, Inc. - Genexine, Inc. - Etubics Corporation - iBio, Inc. - Sirnaomics, Inc. - Cancer Therapeutics CRC Pty Ltd - EyeGene, Inc. - Vaccibody AS - VLP Biotech, Inc. - Coridon Pty Ltd For more information visit http://www.researchandmarkets.com/research/jtm329/human
iBio Receives Patent Allowances for Pandemic Influenza Therapeutics
Marketwire - Thu Mar 27, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S. patents for monoclonal antibodies targeting influenza.
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
iBio to Present at the 26th Annual ROTH Conference on March 10, 2014
Marketwire - Tue Mar 04, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has been invited to present at the 26th Annual ROTH Conference being held March 10-12, 2014 at the Ritz Carlton in Dana Point, California.
PlayStation®4 (PS4(TM)) Sales Surpass 6.0 Million Units Worldwide In Less Than 4 Months Since Launch, Rapidly Popularizes A New Way To Enjoy Social Interaction Through Gaming
PR Newswire - Tue Mar 04, 1:18AM CST
Sony Computer Entertainment Inc. (SCE) today announced that the PlayStation®4 (PS4(TM)) computer entertainment system has cumulatively sold through more than 6.0 million units*1 globally as of March 2, 2014 (JST). This also includes the 370,000 units sold through in Japan since its launch on February 22.
iBio enters Phase 1 clinical trial of malaria vaccine candidate
M2 - Tue Feb 11, 6:42AM CST
US-based plant biotechnology company iBio Inc (NYSE MKT:IBIO) announced on Monday the start of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The candidate is based on its proprietary iBioLaunch platform from the Fraunhofer USA Center for Molecular Biotechnology.
Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology
Marketwire - Mon Feb 10, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The vaccine candidate was produced on the company's proprietary iBioLaunch(TM) platform by the Fraunhofer USA Center for Molecular Biotechnology.
Trypanosomiasis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 07, 2:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2pfn6/trypanosomiasis) has announced the addition of the "Trypanosomiasis - Pipeline Review, H2 2013" report to their offering. 'Trypanosomiasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Trypanosomiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Trypanosomiasis. Scope - A snapshot of the global therapeutic scenario for Trypanosomiasis. - A review of the Trypanosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Trypanosomiasis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Trypanosomiasis Overview Therapeutics Development Pipeline Products for Trypanosomiasis - Overview Pipeline Products for Trypanosomiasis - Comparative Analysis Trypanosomiasis - Therapeutics under Development by Companies Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes Trypanosomiasis - Pipeline Products Glance Early Stage Products Trypanosomiasis - Products under Development by Companies Trypanosomiasis - Products under Investigation by Universities/Institutes Trypanosomiasis - Companies Involved in Therapeutics Development Trypanosomiasis - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Subunit Vaccine For Trypanosomiasis - Drug Profile Xenomycin - Drug Profile Cysteine Proteases Inhibitors - Drug Profile Drug For Parasitic Diseases - Drug Profile Nitrobenzyl Phosphoramide Mustards - Drug Profile Trypanosomiasis - Recent Pipeline Updates Companies Mentioned iBio, Inc. Panacela Labs, Inc. For more information visit http://www.researchandmarkets.com/research/n2...nosomiasis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
iBio Appoints Another IPF Expert, Dr. J. Terrill Huggins, to Clinical Advisory Board
Marketwire - Wed Jul 30, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed J. Terrill Huggins, M.D. to its clinical advisory board. The board of science and medical experts is assisting iBio in its clinical and product strategy.
iBio names Dr Richard M. Silver to clinical advisory board
M2 - Tue Jul 22, 8:30AM CDT
Plant biotechnology company iBio (NYSE MKT:IBIO) revealed on Monday the addition of Dr Richard M. Silver, MD to its clinical advisory board.
iBio Appoints Dr. Richard M. Silver to Clinical Advisory Board
Marketwire - Mon Jul 21, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed Richard M. Silver, M.D. to its recently formed clinical advisory board.
iBio elects Dr Timothy Blackwell as clinical advisory member
M2 - Thu Jul 17, 7:27AM CDT
Plant-based biotechnology company iBio (NYSE MKT:IBIO) disclosed on Wednesday the addition of Timothy Blackwell MD to its newly formed clinical advisory board.
iBio Appoints Dr. Timothy Blackwell to New Clinical Advisory Board
Marketwire - Wed Jul 16, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed Timothy Blackwell, M.D. to its newly formed clinical advisory board.
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lpdgx/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sangamo BioSciences, Inc. - Grifols, S.A. - rEVO Biologics - International Stem Cell Corporation - Kamada Ltd. - Dicerna Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - Applied Genetic Technologies Corporation - Intrexon Corporation - Polyphor Ltd. - iBio, Inc. - OrphageniX, Inc. - Carolus Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4lpdgx/alpha
Yellow Fever - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3x72t/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Yellow Fever - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Arbovax, Inc. - Crucell N.V. - Janssen Pharmaceuticals, Inc. - Medigen, Inc. - Panacea Biotec Limited - Themis Bioscience GmbH - iBio, Inc. For more information visit http://www.researchandmarkets.com/research/l3...llow_fever
iBio Expands Commercial Collaboration With Bio-Manguinhos and Fraunhofer
Marketwire - Wed Jun 18, 1:23AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, amended its multiproduct license and collaboration agreement with Brazil's Bio-Manguinhos/Fiocruz and the Fraunhofer USA Center for Molecular Biotechnology to enable expansion of joint work on an iBioLaunch(TM)-produced recombinant yellow fever vaccine and other products.
iBio awarded US patent for claims covering composition of matter and methods of use for endostatin-related peptides in treating IPF
M2 - Wed Jun 11, 5:37AM CDT
Biotechnology company iBio (NYSE MKT:IBIO) revealed on Tuesday the receipt of a patent from the US Patent and Trademark Office for its idiopathic pulmonary fibrosis (IPF) and systemic sclerosis product pipeline.
iBio Expands IP Protection of Biotherapeutic Product for Treatment of Fibrosis
Marketwire - Tue Jun 10, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the issue by the U.S. Patent and Trademark Office on May 6, 2014 of a new patent covering the company's idiopathic pulmonary fibrosis (IPF) and systemic sclerosis product pipeline.
Fabry Disease - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vktn6c/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Genzyme Corporation - Sanofi - Sangamo BioSciences, Inc. - Amicus Therapeutics, Inc. - Protalix BioTherapeutics, Inc. - Green Cross Corporation - JCR Pharmaceuticals Co., Ltd. - greenovation Biotech GmbH - iBio, Inc. - Neuraltus Pharmaceuticals, Inc. - ISU ABXIS Co.,Ltd. - Biosidus S.A. For more information visit http://www.researchandmarkets.com/research/vk...ry_disease
iBio European Patent on iBioModulator Technology Emerges From Opposition Period
Marketwire - Thu Jun 05, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has surpassed the opposition period, expired on April 10, 2014, for a patent granted to the company by the European Patent Office. There is no indication that the patent has been opposed.
Human papillomavirus (HPV) Associated Cancer Therapeutics Pipeline Review 2014
M2 - Wed May 28, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jtm329/human) has announced the addition of the "Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Merck & Co., Inc. - 3SBio Inc. - Transgene SA - Prima BioMed Ltd. - Antigen Express, Inc. - Bionor Pharma ASA - PDS Biotechnology Corporation - Onconova Therapeutics, Inc. - Genexine, Inc. - Etubics Corporation - iBio, Inc. - Sirnaomics, Inc. - Cancer Therapeutics CRC Pty Ltd - EyeGene, Inc. - Vaccibody AS - VLP Biotech, Inc. - Coridon Pty Ltd For more information visit http://www.researchandmarkets.com/research/jtm329/human
iBio Receives Patent Allowances for Pandemic Influenza Therapeutics
Marketwire - Thu Mar 27, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the allowance of two U.S. patents for monoclonal antibodies targeting influenza.
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
iBio to Present at the 26th Annual ROTH Conference on March 10, 2014
Marketwire - Tue Mar 04, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, has been invited to present at the 26th Annual ROTH Conference being held March 10-12, 2014 at the Ritz Carlton in Dana Point, California.
PlayStation®4 (PS4(TM)) Sales Surpass 6.0 Million Units Worldwide In Less Than 4 Months Since Launch, Rapidly Popularizes A New Way To Enjoy Social Interaction Through Gaming
PR Newswire - Tue Mar 04, 1:18AM CST
Sony Computer Entertainment Inc. (SCE) today announced that the PlayStation®4 (PS4(TM)) computer entertainment system has cumulatively sold through more than 6.0 million units*1 globally as of March 2, 2014 (JST). This also includes the 370,000 units sold through in Japan since its launch on February 22.
iBio enters Phase 1 clinical trial of malaria vaccine candidate
M2 - Tue Feb 11, 6:42AM CST
US-based plant biotechnology company iBio Inc (NYSE MKT:IBIO) announced on Monday the start of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The candidate is based on its proprietary iBioLaunch platform from the Fraunhofer USA Center for Molecular Biotechnology.
Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology
Marketwire - Mon Feb 10, 7:31AM CST
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The vaccine candidate was produced on the company's proprietary iBioLaunch(TM) platform by the Fraunhofer USA Center for Molecular Biotechnology.
Trypanosomiasis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 07, 2:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/n2pfn6/trypanosomiasis) has announced the addition of the "Trypanosomiasis - Pipeline Review, H2 2013" report to their offering. 'Trypanosomiasis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Trypanosomiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Trypanosomiasis. Scope - A snapshot of the global therapeutic scenario for Trypanosomiasis. - A review of the Trypanosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Trypanosomiasis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Trypanosomiasis Overview Therapeutics Development Pipeline Products for Trypanosomiasis - Overview Pipeline Products for Trypanosomiasis - Comparative Analysis Trypanosomiasis - Therapeutics under Development by Companies Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes Trypanosomiasis - Pipeline Products Glance Early Stage Products Trypanosomiasis - Products under Development by Companies Trypanosomiasis - Products under Investigation by Universities/Institutes Trypanosomiasis - Companies Involved in Therapeutics Development Trypanosomiasis - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Subunit Vaccine For Trypanosomiasis - Drug Profile Xenomycin - Drug Profile Cysteine Proteases Inhibitors - Drug Profile Drug For Parasitic Diseases - Drug Profile Nitrobenzyl Phosphoramide Mustards - Drug Profile Trypanosomiasis - Recent Pipeline Updates Companies Mentioned iBio, Inc. Panacela Labs, Inc. For more information visit http://www.researchandmarkets.com/research/n2...nosomiasis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
